Genomind Welcomes New Executive Team Member Thomas Hess

Genomind Welcomes New Executive Team Member Thomas Hess

Mr. Hess will oversee the company’s financials for continued growth.

CHALFONT, PA – October 8, 2014 – Genomind, a personalized medicine company comprised of innovative researchers and expert leaders in psychiatry and neurology, today announced the addition of Thomas P. Hess, CPA, MBA, as Senior Vice President and Chief Financial Officer. Mr. Hess brings robust financial leadership experience inside and outside of the healthcare and biotech industries to Genomind.

“Tom’s background within and outside of the healthcare industry makes him an ideal candidate to join the Genomind leadership team,” said Michael Koffler, President and CEO. “His unique background and successful track record with innovative growth companies is a key ingredient to our continued growth and success.”

Mr. Hess has held various financial leadership positions for more than a decade, including; Chief Financial Officer and Executive Vice President of Keane. With significant biotech experience, he also served as Chief Financial Officer for Yaupon Therapeutics and Adolor Corporation, which were development stage biotechnology companies each of which successfully launched an FDA approved drug. Mr. Hess also served as the Corporate Controller for Vicuron Pharmaceuticals (now part of Pfizer), and as a controller for several technology companies. Mr. Hess is a CPA and Adjunct Professor at DeSales University, and is active in Pennsylvania Bio. He received a BS in Accounting from Pennsylvania State University and an MBA from the University of Pittsburgh – Katz Graduate School of Business.

“I am fortunate to join Genomind at such an exciting time for the company,” said Mr. Hess. “Genomind is focused on advancing the mental health field with a very innovative and personalized approach, and I believe that Genomind is ahead of the competition.”

About Genomind

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at

About the Genecept Assay

The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit

For more information, contact:

Adam Shapiro

Amy Pressman
Marketing Manager, Genomind


} ); } ( jQuery ) );